These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8655118)

  • 41. Outcome and prognosis of cyclosporine-related hemolytic-uremic syndrome in kidney graft recipients: clinical and histopathologic study of 13 cases.
    Bren AF; Kandus A; Koselj M; Buturovic J; Lindic J; Kovac D; Ponikvar R; Vizjak A; Ferluga D
    Transplant Proc; 2002 Nov; 34(7):3005-6. PubMed ID: 12431685
    [No Abstract]   [Full Text] [Related]  

  • 42. [The pathogenesis, diagnosis and therapy of posttransplantation osteoporosis].
    Hofbauer LC; Heufelder AE
    Dtsch Med Wochenschr; 1996 Jul; 121(30):953-7. PubMed ID: 8765705
    [No Abstract]   [Full Text] [Related]  

  • 43. Cyclosporine and lipid peroxidation.
    Kasiske BL
    Am J Kidney Dis; 1998 Jan; 31(1):149-51; discussion 151-4. PubMed ID: 9428467
    [No Abstract]   [Full Text] [Related]  

  • 44. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation.
    Miller BW; Hmiel SP; Schnitzler MA; Brennan DC
    Am J Kidney Dis; 1997 May; 29(5):813-4. PubMed ID: 9159323
    [No Abstract]   [Full Text] [Related]  

  • 45. Cyclosporine and posttransplant hypertension.
    Curtis JJ
    J Am Soc Nephrol; 1992 Jun; 2(12 Suppl):S243-5. PubMed ID: 1498282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Myopathy with ragged red fibres following renal transplantation: possible role of cyclosporin-induced hypomagnesaemia.
    Larner AJ; Sturman SG; Hawkins JB; Anderson M
    Acta Neuropathol; 1994; 88(2):189-92. PubMed ID: 7985501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypercoagulable state as a risk factor in transplantation.
    Edwards CM; Morgan JD; Donnelly PK
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1051. PubMed ID: 8442038
    [No Abstract]   [Full Text] [Related]  

  • 48. Cyclosporine A neurotoxicity in a patient with idiopathic renal magnesium wasting.
    Al-Rasheed AK; Blaser SI; Minassian BA; Benson L; Weiss SK
    Pediatr Neurol; 2000 Oct; 23(4):353-6. PubMed ID: 11068171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interaction between lovastatin and cyclosporine A after heart and kidney transplantation.
    Gullestad L; Nordal KP; Berg KJ; Cheng H; Schwartz MS; Simonsen S
    Transplant Proc; 1999 Aug; 31(5):2163-5. PubMed ID: 10456002
    [No Abstract]   [Full Text] [Related]  

  • 50. Asymptomatic hyperamylasemia after cyclosporine therapy in patients with renal transplants.
    Prevost X; Myara I; Cosson C; Duboust A; Moatti N
    Transplant Proc; 1988 Jun; 20(3):555-8. PubMed ID: 2454523
    [No Abstract]   [Full Text] [Related]  

  • 51. Cortical hyperintensity on proton density-weighted images: An MR sign of cyclosporine-related encephalopathy.
    Jansen O; Krieger D; Krieger S; Sartor K
    AJNR Am J Neuroradiol; 1996 Feb; 17(2):337-44. PubMed ID: 8938308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic approach to renal transplantation: triple therapy and beyond.
    Leichtman AB; Strom TB
    Transplant Proc; 1988 Dec; 20(6 Suppl 8):1-6. PubMed ID: 3059618
    [No Abstract]   [Full Text] [Related]  

  • 53. Cyclosporin induces magnesium deficiency in rats and thereby aggravates its own nephrotoxicity: benefit of magnesium supplementation.
    Rob PM; Lebeau A; Schmid H; Sack K; Classen HG
    Transplant Proc; 1994 Jun; 26(3):1736-7. PubMed ID: 8030111
    [No Abstract]   [Full Text] [Related]  

  • 54. [Effects of cyclosporin A on various indices of cholestasis in kidney transplant recipients].
    Soresi M; Sparacino V; Pisciotta G; Bonfissuto G; Caputo F; Carroccio A; Calabrese S; Montalto G
    Minerva Urol Nefrol; 1995 Jun; 47(2):65-9. PubMed ID: 8560351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Malignant tumors following kidney transplantation. Experiences at the tranplantation center in Zurich].
    Wegmann W; Largiadèr F; Binswanger U
    Schweiz Med Wochenschr; 1974 Jun; 104(23):809-14. PubMed ID: 4601389
    [No Abstract]   [Full Text] [Related]  

  • 56. Pathogenesis of cyclosporine-induced hypomagnesemia.
    Nozue T; Kobayashi A; Kodama T; Uemasu F; Endoh H; Sako A; Takagi Y
    J Pediatr; 1992 Apr; 120(4 Pt 1):638-40. PubMed ID: 1552407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclosporine-induced folliculodystrophy.
    Heaphy MR; Shamma HN; Hickmann M; White MJ
    J Am Acad Dermatol; 2004 Feb; 50(2):310-5. PubMed ID: 14726894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistent cortical blindness after cyclosporine leukoencephalopathy.
    Casanova B; Prieto M; Deya E; Gisbert C; Mir J; Berenguer J; Vilchez JJ
    Liver Transpl Surg; 1997 Nov; 3(6):638-40. PubMed ID: 9404966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclosporine avoidance.
    Gauthier P; Helderman JH
    J Am Soc Nephrol; 2000 Oct; 11(10):1933-1936. PubMed ID: 11004226
    [No Abstract]   [Full Text] [Related]  

  • 60. Parapoxvirus Orf in kidney transplantation.
    Peeters P; Sennesael J
    Nephrol Dial Transplant; 1998 Feb; 13(2):531. PubMed ID: 9509488
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.